



[Home](#) / [News](#) / [Detail](#) /

Democratic Republic of the Congo begins first-ever multi-drug Ebola trial

Democratic Republic of the Congo begins first-ever multi-drug Ebola trial

26 November 2018 | News Release



The Ministry of Health of the Democratic Republic of the Congo (DRC) today announced that a randomized control trial has begun to evaluate the effectiveness and safety of drugs used in the treatment of Ebola patients. The trial is the first-ever multi drug trial for an Ebola treatment. It will form part of a multi-outbreak, multi-country study that was agreed to by partners under a World Health Organization (WHO) initiative.

“While our focus remains on bringing this outbreak to an end, the launch of the randomized control trial in DRC is an important step towards finally finding an Ebola treatment that will save lives,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Until now, patients have

been treated under a compassionate use protocol, with drugs that showed promise and had a good safety profile in laboratory conditions. The giant step DRC is taking now will bring clarity about what works best, and save many lives in years to come. We hope to one day say that the death and suffering from Ebola is behind us.”

Until now, over 160 patients have been treated with investigational therapeutics under an ethical framework developed by WHO, in consultation with experts in the field and the DRC, called the [Monitored Emergency Use of Unregistered and Investigational Interventions](#) (MEURI). The MEURI protocol was not designed to evaluate the drugs. Now that protocols for trials are in place, patients will be offered treatments under that framework in the facilities where the trial has started. In others, compassionate use will continue up to the time when they join the randomization. Patients will not be treated noticeably differently from before, though the treatment they receive will be decided by random allocation. The data gathered will become standardized and will be useful for drawing conclusions about the safety and efficacy of the drugs.

“Our country is struck with Ebola outbreaks too often, which also means we have unique expertise in combatting it,” said Dr Olly Ilunga, Minister of Health of the DRC. “These trials will contribute to building that knowledge, while we continue to respond on every front to bring the current outbreak to an end.”

In October, WHO convened a meeting of international organizations, United Nations partners, countries at risk of Ebola, drug manufacturers and others to agree on a framework to continue trials in the next Ebola outbreak, whenever and wherever that is. Over time, this will lead to an accumulation of evidence that will help to draw robust conclusions across outbreaks about the currently available drugs, and any new ones that may come along.

At the heart of the long term plan and the current trial is always the goal to ensure that patients with Ebola and their communities are treated with respect and fairness. All patients should be provided with the highest level of care and have access to the most promising medications.

The current trial is coordinated by WHO, and led and sponsored by the DRC’s National Institute for Biomedical Research (INRB), in partnership with the DRC Ministry of Health, the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the United States’ National Institutes of Health, The Alliance for International Medical Action (ALIMA) and other organizations.

The deliberations of the consultation are available [here](#).

Want to read more?

Subscribe to newsletter →

facts

Tarik Jasarevic

Spokesperson / Media

Relations

WHO

Telephone:
[+41227915099](tel:+41227915099)
Mobile:
[+41793676214](tel:+41793676214)
Email:
jasarevict@who.int

News

**WHO
statement
on latest
attacks in
the
Democratic
Republic of
the Congo**

17 November
2018

**New
measures
and strong
partnership
having
positive
impact on
Ebola
response
in the
Democratic
Republic of
the Congo**

8 November
2018

Fact sheets

**Ebola
virus
disease**

12
February
2018

**Statement
on the
October
2018
meeting of
the IHR
Emergency
Committee
on the
Ebola virus
disease
outbreak in
the
Democratic
Republic of
the Congo**

Feature stories

**Ebola
vaccine
provides
protection
and hope for
high-risk
communities
in the
Democratic
Republic of
the Congo**

30 May 2018

What we do

Health Topics
Countries
Programmes
Frequently asked questions
Employment

Regions

Africa
Americas
South-East Asia
Europe
Eastern Mediterranean
Western Pacific

About us

Director-General
World Health Assembly
Executive Board
Member States
Ethics

Contact

Contact
us

Feedback

**Subscribe
to our
newsletter**

Privacy Legal Notice

© 2018 WHO